SFA Therapeutics Announces Updated Psoriasis Data for SFA-002, Bridge Financing, and Foundational Patent

2 years ago

SFA-002 Updated Extension Data Showing 92% PASI 50 and 72% PASI 75$4.5 Million Bridge Financing led by North South VenturesComposition…

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Island Ambulatory Surgery Center in Brooklyn, New York

2 years ago

Represents first sales by the Company into an ambulatory surgery center Follows successful evaluation by Island Ambulatory Surgery Center’s founder…

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

2 years ago

- Company Now Focused on Proprietary Drug-Eluting Biomatrix Platform - SILVER SPRING, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Elutia…

New Shockwave Coronary IVL Publication Shows Similar Outcomes in Women And Men

2 years ago

One-Year Outcomes Published in JSCAI Confirm Excellent, Consistent IVL Safety and Effectiveness Across SexesSANTA CLARA, Calif., Nov. 09, 2023 (GLOBE…

Pharma Two B Announces Publication of Positive Phase 3 Study Results of P2B001, an Investigational Treatment for Early Parkinson’s Disease, in Movement Disorders

2 years ago

Demonstrated that P2B001 provides benefits comparable with commercially used doses of marketed pramipexole-ER (PramiER) while minimizing associated daytime sleep–related and…

Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit

2 years ago

SEATTLE, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of…

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

2 years ago

Completed enrollment of BEACON and AURORA trials of bitopertin in erythropoietic protoporphyria (EPP); BEACON expanded to include adolescentsData from all…

Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

2 years ago

Reported preliminary clinical data from the pivotal NAVAL-1 clinical trial of Nana-val in patients with relapsed or refractory EBV+ peripheral…

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

2 years ago

HANOVER, MD, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical…

Maravai LifeSciences Announces November 2023 Investor Conference Schedule

2 years ago

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents…